Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma.
作者信息
Harada Kazuto, Song Shumei, Baba Hideo, Ajani Jaffer A
机构信息
Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.
出版信息
Shanghai Chest. 2017 Nov;1. doi: 10.21037/shc.2017.10.07. Epub 2017 Nov 8.
Abstract
摘要
相似文献
1
Is phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway therapeutic target for esophageal adenocarcinoma.磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶标通路是食管腺癌的治疗靶点吗？
Shanghai Chest. 2017 Nov;1. doi: 10.21037/shc.2017.10.07. Epub 2017 Nov 8.
2
Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IκB kinase activity.肝细胞生长因子诱导的 c-Src-磷酸肌醇 3-激酶-AKT-雷帕霉素靶蛋白通路通过抑制 IκB 激酶活性抑制树突状细胞的激活。
Int J Biochem Cell Biol. 2011 Aug;43(8):1134-46. doi: 10.1016/j.biocel.2011.04.006. Epub 2011 Apr 19.
3
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.抑制磷脂酰肌醇3-激酶/蛋白激酶B/雷帕霉素哺乳动物靶标信号通路而非丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路，可减弱层粘连蛋白介导的小细胞肺癌细胞存活以及对甲磺酸伊马替尼或化疗的耐药性。
Cancer Res. 2005 Sep 15;65(18):8423-32. doi: 10.1158/0008-5472.CAN-05-0058.
4
The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy.食管癌与 PI3K/AKT/mTOR 信号转导调控 microRNAs：一种新的预后标志物，和免疫治疗的可能靶点。
Curr Pharm Des. 2018;24(39):4646-4651. doi: 10.2174/1381612825666190110143258.
5
LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.LY303511（2-哌嗪基-8-苯基-4H-1-苯并吡喃-4-酮）通过不依赖磷脂酰肌醇3-激酶的途径，经雷帕霉素哺乳动物靶标（mTOR）依赖性和非mTOR依赖性机制抑制细胞增殖。
J Pharmacol Exp Ther. 2005 Sep;314(3):1134-43. doi: 10.1124/jpet.105.083550. Epub 2005 May 27.
6
Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.磷酸化哺乳动物雷帕霉素靶蛋白的表达与食管鳞癌患者放化疗反应的关系。
J Thorac Cardiovasc Surg. 2012 Dec;144(6):1352-9, 1359.e1. doi: 10.1016/j.jtcvs.2012.06.049. Epub 2012 Jul 25.
7
Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.MCF-7乳腺癌细胞中胰岛素样生长因子结合蛋白-2的表达通过磷脂酰肌醇3-激酶/AKT/雷帕霉素哺乳动物靶标途径进行调控。
Endocrinology. 2007 May;148(5):2532-41. doi: 10.1210/en.2006-1335. Epub 2007 Feb 8.
8
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.高血糖症与I期试验中的磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶点（PI3K/AKT/mTOR）抑制剂：发生率、预测因素及管理
Oncologist. 2016 Jul;21(7):855-60. doi: 10.1634/theoncologist.2015-0248. Epub 2016 May 5.
9
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.长链非编码 RNA (lncRNA) 生长停滞特异性 5 (GAS5) 通过抑制磷脂酰肌醇 3-激酶 (PI3K)/AKT/雷帕霉素靶蛋白 (mTOR) 信号通路抑制食管鳞状细胞癌细胞增殖和迁移。
Med Sci Monit. 2018 Oct 28;24:7689-7696. doi: 10.12659/MSM.910867.
10
Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.神经母细胞瘤中磷脂酰肌醇 3-激酶/AKT 通路的激活及其受硫氧还蛋白 1 的调节。
Hum Pathol. 2011 Nov;42(11):1727-39. doi: 10.1016/j.humpath.2011.01.019.
本文引用的文献
1
Integrated genomic characterization of oesophageal carcinoma.食管癌的综合基因组特征分析
Nature. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4.
2
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.全球、区域和国家癌症发病率、死亡率、生命损失年数、失能生存年数以及 32 种癌症组别的伤残调整生命年数，1990 年至 2015 年：全球疾病负担研究的系统分析。
JAMA Oncol. 2017 Apr 1;3(4):524-548. doi: 10.1001/jamaoncol.2016.5688.
3
PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.PTEN 缺失与曲妥珠单抗治疗 HER2 过表达胃食管腺癌的应答不良相关。
Gastric Cancer. 2017 May;20(3):416-427. doi: 10.1007/s10120-016-0627-z. Epub 2016 Aug 12.
4
PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.PI3K/mTOR双重抑制剂LY3023414在大鼠模型中对食管腺癌显示出强大的抗肿瘤功效。
Ann Surg. 2017 Jul;266(1):91-98. doi: 10.1097/SLA.0000000000001908.
5
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.PIK3CA突变在胃癌中的预后及临床影响：焦磷酸测序技术与文献综述
BMC Cancer. 2016 Jul 7;16:400. doi: 10.1186/s12885-016-2422-y.
6
AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy.AKT表达与接受新辅助治疗的食管腺癌的病理反应程度相关。
J Gastrointest Oncol. 2016 Apr;7(2):158-65. doi: 10.3978/j.issn.2078-6891.2015.067.
7
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.维莫非尼治疗转移性BRAF突变型结直肠癌患者的II期探索性研究
J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497. Epub 2015 Oct 12.
8
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.信号输出的滴定：对MEK和AKT抑制剂临床联合应用的见解
Ann Oncol. 2015 Jul;26(7):1504-10. doi: 10.1093/annonc/mdv188. Epub 2015 Apr 23.
9
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
10
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.依维莫司治疗既往治疗的晚期胃癌：随机、双盲、III 期 GRANITE-1 研究结果。
J Clin Oncol. 2013 Nov 1;31(31):3935-43. doi: 10.1200/JCO.2012.48.3552. Epub 2013 Sep 16.
Zotero 插件